Intravenous Golimumab found Effective in Rheumatoid Arthritis Patients Switching Directly from Infliximab

Primary tabs

NEWS
Intravenous Golimumab found Effective in Rheumatoid Arthritis Patients Switching Directly from Infliximab

The intravenous administration of Golimumab effectively managed rheumatoid arthritis among patients switching directly from Infliximab, confirms a recent study published in "Drugs in R & D" Journal.

Direct shifting from one anti-TNF to other anti-TNF may help to reduce disease expansion. Vance J. Bray and colleagues conducted an analysis to assess Golimumab efficacy and utilization through real-world RA population who directly shifted from Infliximab to intravenous Golimumab.

Patient charts were extracted from five US-based rheumatology practices. Overall, 113 patients charts were assessed for treatment characteristics, intravenous Golimumab and Infliximab utilization data, patient demographics along with Routine Assessment of Patient Index Data (RAPID3) scores, Clinical Disease Activity Index (CDAI), Physician Global Assessment (PhGA) and Patient Global Assessment (PtGA). A comparison of pre- and post IV Golimumab induction was done to evaluate its efficacy.

A considerable decline was seen in disease activity, mean PhGA and CDAI scores after shifting to IV Golimumab whereas, PtGA and RAPID3 scores exhibited minimal changes. During the post IV Golimumab period, the significant portion of the population showed a remarkable reduction in disease activity(p < 0.05).

Source

Drugs             

Link:

https://www.ncbi.nlm.nih.gov/pubmed/30054896

The original title of article:

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients

Authors:

Vance J. Bray et al.

SearchTags: 
Therapeutic, Golimumab, Infliximab, Rheumatoid Arthritis, Joints, TNF Inhibitors, Efficacy, Intravenous
Log in or register to post comments